Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

Clinical Trial of Expanded and Activated Autologous NK Cells to Treat Multiple Myeloma (NK-VS-MM)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT02481934
Recruitment Status : Completed
First Posted : June 25, 2015
Results First Posted : December 5, 2016
Last Update Posted : April 17, 2017
Sponsor:
Collaborator:
Hospital Infantil Universitario Niño Jesús, Madrid, Spain
Information provided by (Responsible Party):
Joaquín Martínez López, MD, PhD, Hospital Universitario 12 de Octubre

Brief Summary:
The purpose of this study is to determine wether activated and expanded autologous Natural Killer cells (NKAEs) are effective in the treatment of patients with multiple myeloma on second or later relapse. NKAEs are used in combination with anti-myeloma drugs such as lenalidomide or bortezomib.

Condition or disease Intervention/treatment Phase
Multiple Myeloma Procedure: NKAE cells infusion Drug: Lenalidomide Drug: Bortezomib Phase 1

Detailed Description:

It is expected to enroll 10 to 15 patients within 18 months. Patients have to achieve stable disease after induction therapy. Peripheral blood from patients will be collected every cycle (n=4) to produce NKAEs under Good Manufacturing Practice (GMP) conditions peripheral blood mononuclear cell (PBMCs) will be co-cultured with a genetically modified cell line (K562-mb15-41BBL) and 100 IU/ml interleukin-2.

Treatment consists of 4 cycles of anti-myeloma consolidation treatment with two infusions of NKAEs every day 1 and 8 of each cycle. Usually, chosen treatment regime will be bortezomib (Velcade) or lenalidomide (Revlimid). These treatments are used to be combined with corticosteroid medications which needs to be suspended before NKAEs infusions. A washout period of 2 weeks is required.

NKAEs dose of cells will be constant, 7.5x106/kg. There will be an interim analysis intra-cohort one week after the first batch of two infusions. If at the analysis no grade IV adverse effect is observed we will proceed to the second cycle and the inclusion of other patients.


Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 5 participants
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Phase 1 Clinical Trial to Evaluate Security and Dose of Expanded and Activated Autologous NK Cells Infusions in Consolidation of Multiple Myeloma Patients Treatment on Second or Later Relapse.
Study Start Date : March 2013
Actual Primary Completion Date : July 2016
Actual Study Completion Date : October 2016

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Multiple Myeloma

Arm Intervention/treatment
Experimental: NKAE cells infusion + chemotherapy
Expanded and activated autologous NK cells (NKAEs) + chemotherapy (lenalidomide OR bortezomib).
Procedure: NKAE cells infusion
Expanded and activated autologous NK cells infusion. Each patient will receive two infusions of 7.5 x 106 expanded and activated autologous NK cells/kg/cycle.
Other Names:
  • NKAE infusion
  • Activated and expanded autologous NK cells infusion

Drug: Lenalidomide
Lenalidomide, 10 mg oral/day during 21 days (cycle). Patients will receive 4 cycles.
Other Name: Revlimid

Drug: Bortezomib
Bortezomib, 1.3 mg/m2, s.c., days 1, 4, 8 and 11/cycle. Patients will receive 4 cycles.
Other Name: Velcade




Primary Outcome Measures :
  1. Number of Participants With Adverse Events During NKAE Treatment [ Time Frame: 16 months ]
    Toxicity will be assessed by adverse events count during NKAE treatment monitoring peripheral blood absolute neutrophil count (cells/μl). Toxicity will be evaluated monthly during NKAE treatment (4 months). During follow-up, it will be assessed monthly the first 6 months. After that, quarterly until one year of follow-up, based on Common Toxicity Criteria for Adverse Events of the National Cancer Institute (CTCAE) to v.4.03.


Secondary Outcome Measures :
  1. Number of Participants With Peripheral Blood Monoclonal Protein Reduction or Stabilization [ Time Frame: 16 months ]
    Efficacy will be assessed monthly during NKAE treatment (4 months) by peripheral blood monoclonal protein monitoring. During follow-up, efficacy will be evaluated monthly the first 6 months. After that, quarterly until one year of follow-up.



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   20 Years to 80 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Subjects between 20 and 80 years old
  • With multiple myeloma in 2nd or later relapse or showing resistance after 2 treatment lines
  • Eastern Cooperative Oncology Group (ECOG) ≤ 2
  • Life expectancy greater than six months
  • Creatinine clearance rate more than 30 ml / min
  • Subjects who have received at least 4 cycles of rescue treatment under the procedures of the 12 de Octubre Hospital (rescue treatment will vary depending on previous anti-myeloma treatment). After treatment, patients must have shown chemosensitivity and disease stabilization.
  • Will be included subjects with partial response or stable disease (for at least 2 cycles) after 75% of planned rescue treatment or patients at subclinical progression (defined as an increase of monoclonal component ≥ 25%) at any time of rescue treatment. Subjects have to show tolerance to rescue treatment, without G3/4 adverse effects, if G1/2 adverse effects exist they must be analyzed immediately before starting reinfusion program.
  • Subjects have to agree to participate in the trial and they have to sign informed consent.

Exclusion Criteria:

  • Subjects with clinical progression or complete response will not be included.
  • Any of the following abnormal laboratory results:

Absolute Neutrophil Count < 1000/ µL Platelets Count < 50000/ µL in those patients with bone marrow infiltration lower than 50% Measured creatinine clearance <30 ml/min Hemoglobin level ≤ 8 g/dL Peripheral neuropathy ≥ Grade 2

  • Subjects have received allogeneic stem cell transplant.
  • Subjects with heart disease which compromises patient's life or protocol accomplishment.
  • Subjects with past clinical history of malignant disease within 3 years (exceptions are squamous or basal cell carcinoma).
  • Subjects receiving another investigational drug or having received investigational drug within 30 days before screening.
  • Subjects who require chronic steroid or immunosuppressive treatment.
  • Any condition, including abnormally laboratory results, that might compromise the patient´s life if he participate in this study.
  • Any concurrent medical condition, abnormally laboratory results or any psychological disorder that prevent the patient to sign the informed consent.
  • Pregnant or fertile women.
  • Patients known to be seropositive for human immunodeficiency virus (VIH) or having active hepatitis A, B or C.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02481934


Locations
Layout table for location information
Spain
Hospital Universitario 12 de Octubre
Madrid, Spain, 28041
Sponsors and Collaborators
Joaquín Martínez López, MD, PhD
Hospital Infantil Universitario Niño Jesús, Madrid, Spain
Investigators
Layout table for investigator information
Principal Investigator: Joaquín Martínez López, M.D, Ph.D Hospital Universitario 12 de Octubre

Layout table for additonal information
Responsible Party: Joaquín Martínez López, MD, PhD, Hematology Head of department, M.D., Ph.D., Hospital Universitario 12 de Octubre
ClinicalTrials.gov Identifier: NCT02481934     History of Changes
Other Study ID Numbers: NK-VS-MM
First Posted: June 25, 2015    Key Record Dates
Results First Posted: December 5, 2016
Last Update Posted: April 17, 2017
Last Verified: March 2017
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: Undecided
Keywords provided by Joaquín Martínez López, MD, PhD, Hospital Universitario 12 de Octubre:
Recurrent multiple myeloma
NK cells
cell therapy
NKAE
Relapsed multiple myeloma
Additional relevant MeSH terms:
Layout table for MeSH terms
Multiple Myeloma
Neoplasms, Plasma Cell
Neoplasms by Histologic Type
Neoplasms
Hemostatic Disorders
Vascular Diseases
Cardiovascular Diseases
Paraproteinemias
Blood Protein Disorders
Hematologic Diseases
Hemorrhagic Disorders
Lymphoproliferative Disorders
Immunoproliferative Disorders
Immune System Diseases
Lenalidomide
Bortezomib
Immunologic Factors
Physiological Effects of Drugs
Angiogenesis Inhibitors
Angiogenesis Modulating Agents
Growth Substances
Growth Inhibitors
Antineoplastic Agents